{"DataElement":{"publicId":"3104050","version":"3","preferredName":"Follow-up Assessment Therapy Outcome Success Type","preferredDefinition":"Text term that represents the kind of outcome success at the completion of the follow-up submission.","longName":"3104048v1.0:2786719v3.1","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3104048","version":"1","preferredName":"Follow-up Assessment Outcome Success","preferredDefinition":"_The final result of a determination of the value, significance, or extent of._The process by which information about the health status of an individual is obtained after a study has officially closed._The result of an action._An event that accomplishes its intended purpose.","longName":"2481104v1.0:2786715v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2481104","version":"1","preferredName":"Follow-up Assessment","preferredDefinition":"The process by which information about the health status of an individual is obtained after a study has officially closed.:The final result of a determination of the value, significance, or extent of.","longName":"C16033:C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follow-Up","conceptCode":"C16033","definition":"The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1373639F-304E-418B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-10","modifiedBy":"ONEDATA","dateModified":"2006-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2786715","version":"1","preferredName":"Outcome Success","preferredDefinition":"Outcome; a phenomenon that follows and is caused by some previous phenomenon.:Success; an event that accomplishes its intended purpose.","longName":"C20200:C25362","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Success","conceptCode":"C25362","definition":"An event that accomplishes its intended purpose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5758397B-E829-370D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-09-20","modifiedBy":"ONEDATA","dateModified":"2008-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87B09146-B36B-5BA7-E040-BB89AD4344F3","latestVersionIndicator":"Yes","beginDate":"2010-05-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2786719","version":"3.1","preferredName":"Therapy Outcome Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The result of an action._Type; a subdivision of a particular kind of thing.","longName":"2786719v3.1","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Complete Remission/Response","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-18D9-57DE-E050-BB89AD437A36","beginDate":"2010-10-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Persistent Disease","valueDescription":"Persistent disease (Hematologic persistence)","ValueMeaning":{"publicId":"3178994","version":"1","preferredName":"Persistent disease (Hematologic persistence)","longName":"3178994","preferredDefinition":"A disease that does not go to remission despite treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Persistent Disease","conceptCode":"C90169","definition":"A disease that does not go to remission despite treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"986B514C-4AE1-E2CB-E040-BB89AD433A07","latestVersionIndicator":"Yes","beginDate":"2010-12-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-12-27","modifiedBy":"SOKKERL","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-18E3-57DE-E050-BB89AD437A36","beginDate":"2010-01-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"2838911","version":"1","preferredName":"Not Applicable","longName":"2838911","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A641-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"CLOHNES","dateModified":"2022-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-18ED-57DE-E050-BB89AD437A36","beginDate":"2008-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Partial Remission/Response","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"2577916","version":"1","preferredName":"Partial Remission","longName":"2577916","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD69-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-18F7-57DE-E050-BB89AD437A36","beginDate":"2008-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Progressive Disease","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-1901-57DE-E050-BB89AD437A36","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Stable Disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"3008097","version":"1","preferredName":"Stable Disease","longName":"3008097","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F18900C-CCD8-E3F0-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-02-08","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-190B-57DE-E050-BB89AD437A36","beginDate":"2008-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-1915-57DE-E050-BB89AD437A36","beginDate":"2008-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Progressive Tumor Mass and Tumor Markers","valueDescription":"Progressive Tumor Mass and Tumor Markers","ValueMeaning":{"publicId":"4592311","version":"1","preferredName":"Progressive Tumor Mass and Tumor Markers","longName":"4592311","preferredDefinition":"Advancing in extent or severity.: A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.: A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).: An observation confirming something, such as the presence of a disease, condition, or microorganism.: Cancer that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive","conceptCode":"C25254","definition":"Advancing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Mass","conceptCode":"C34808","definition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C45DB0-A817-F70B-E050-BB89AD432ABC","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-191F-57DE-E050-BB89AD437A36","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Normalization of Tumor Markers, but Residual Tumor Mass","valueDescription":"Normalization of Tumor Markers, but Residual Tumor Mass","ValueMeaning":{"publicId":"4592312","version":"1","preferredName":"Normalization of Tumor Markers, but Residual Tumor Mass","longName":"4592312","preferredDefinition":"A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: Cancer cells that remain after attempts to remove the cancer have been made.: Being or existing in a specified place or at the specified time.: A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Residual Disease","conceptCode":"C4809","definition":"Tumor cells that remain in the body following cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C45DB0-A840-F70B-E050-BB89AD432ABC","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-1929-57DE-E050-BB89AD437A36","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"No Measureable Tumor or Tumor Markers","valueDescription":"No Measureable Tumor or Tumor Markers","ValueMeaning":{"publicId":"4592313","version":"1","preferredName":"No Measureable Tumor or Tumor Markers","longName":"4592313","preferredDefinition":"Capable of being measured.: A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: Not existing in a specified place at a specified time.: A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).: A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable","conceptCode":"C37894","definition":"Capable of being measured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Absent","conceptCode":"C48190","definition":"Not existing in a specified place at a specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C45DB0-A86A-F70B-E050-BB89AD432ABC","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-1933-57DE-E050-BB89AD437A36","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Elevated Tumor Markers and Residual Mass","valueDescription":"Elevated Tumor Markers and Residual Mass","ValueMeaning":{"publicId":"4592314","version":"1","preferredName":"Elevated Tumor Markers and Residual Mass","longName":"4592314","preferredDefinition":"Raised or increased above normal levels or limits.: A substance that may be found in tumor tissue or released from a tumor into the blood or other body fluids. A high level of a tumor marker may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (in ovarian cancer), CA 15-3 (in breast cancer), CEA (in ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (in prostate cancer).: Remaining or left behind.: A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.: A disease that does not go to remission despite treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mass","conceptCode":"C34808","definition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells, inflammatory cells, or cystic changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Persistent Disease","conceptCode":"C90169","definition":"A disease that does not go to remission despite treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C45DB0-A893-F70B-E050-BB89AD432ABC","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"07C32E78-193D-57DE-E050-BB89AD437A36","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"ONEDATA","dateModified":"2014-11-13","deletedIndicator":"No"},{"value":"Treatment Ongoing","valueDescription":"Treatment Still in Progress","ValueMeaning":{"publicId":"5102336","version":"1","preferredName":"Treatment Still in Progress","longName":"5102336","preferredDefinition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Continue","conceptCode":"C53279","definition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-02E0-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2A5DB38D-EBB6-8A01-E050-BB89AD435388","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-27","modifiedBy":"ONEDATA","dateModified":"2016-01-27","deletedIndicator":"No"},{"value":"First Course Treatment Still in Progress","valueDescription":"First Course Treatment Still in Progress","ValueMeaning":{"publicId":"5102183","version":"1","preferredName":"First Course Treatment Still in Progress","longName":"5102183","preferredDefinition":"Preceding all others in time or space or degree.: Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.: Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Continue","conceptCode":"C53279","definition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"293DD10B-BF0C-AC49-E050-BB89AD436922","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"293DD10B-BF25-AC49-E050-BB89AD436922","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Treatment Stopped Due to Toxicity","valueDescription":"Treatment Terminated Due to Toxicity","ValueMeaning":{"publicId":"5102184","version":"1","preferredName":"Treatment Terminated Due to Toxicity","longName":"5102184","preferredDefinition":"Indicates that the patient terminated the treatment due to toxicity related to the treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treatment Terminated Due to Toxicity","conceptCode":"C105741","definition":"Indicates that the patient terminated the treatment due to toxicity related to the treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"293DD10B-BF31-AC49-E050-BB89AD436922","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"293DD10B-BF4A-AC49-E050-BB89AD436922","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29400305-02D6-73D5-E050-BB89AD437D83","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Partial Response","valueDescription":"Partial Response","ValueMeaning":{"publicId":"3009200","version":"1","preferredName":"Partial Response","longName":"3009200","preferredDefinition":"Partial; being or affecting only a part; not total: In medicine, an improvement related to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial","conceptCode":"C25378","definition":"Being or affecting only a part of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F57A4E6-FF10-4596-E040-BB89AD432406","latestVersionIndicator":"Yes","beginDate":"2010-02-11","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29400305-030D-73D5-E050-BB89AD437D83","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Complete Response","valueDescription":"Complete Response","ValueMeaning":{"publicId":"5102337","version":"1","preferredName":"Complete Response","longName":"5102337","preferredDefinition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-0318-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29400305-0330-73D5-E050-BB89AD437D83","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"No Response","valueDescription":"No Response","ValueMeaning":{"publicId":"5654573","version":"1","preferredName":"No Response","longName":"5654573","preferredDefinition":"No apparent change or worsening in tumor staging classification.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Response","conceptCode":"C123600","definition":"No apparent change or worsening in lesion staging classification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E126E3-C3C0-533A-E053-F662850A36AA","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67EC59D4-9FF9-368F-E053-F662850A9BCD","beginDate":"2018-03-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-21","modifiedBy":"ONEDATA","dateModified":"2018-03-21","deletedIndicator":"No"},{"value":"Mixed Response","valueDescription":"Mixed response","ValueMeaning":{"publicId":"2738405","version":"1","preferredName":"Mixed response","longName":"2738405","preferredDefinition":"Involving or composed of different kinds.: The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed","conceptCode":"C25259","definition":"Involving or composed of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BC9518-CC95-1A72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67EC59D4-A00E-368F-E053-F662850A9BCD","beginDate":"2018-03-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-21","modifiedBy":"ONEDATA","dateModified":"2018-03-21","deletedIndicator":"No"},{"value":"Very Good Partial Response","valueDescription":"Very good Partial Response","ValueMeaning":{"publicId":"3669391","version":"1","preferredName":"Very good Partial Response","longName":"3669391","preferredDefinition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very Good Partial Response","conceptCode":"C123618","definition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4813252-CCB5-71BE-E040-BB89AD4341ED","latestVersionIndicator":"Yes","beginDate":"2013-01-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept annotation. mc 4/11/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67EC59D4-A023-368F-E053-F662850A9BCD","beginDate":"2018-03-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-21","modifiedBy":"ONEDATA","dateModified":"2018-03-21","deletedIndicator":"No"},{"value":"No Measurable Disease","valueDescription":null,"ValueMeaning":{"publicId":"13258420","version":"1","preferredName":"No Measurable or Evaluable Disease","longName":"13258420v1.00","preferredDefinition":"An absence of quantifiable or detectable disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Measurable or Evaluable Disease","conceptCode":"C7919","definition":"An absence of quantifiable or detectable disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7F6B052-E84B-4AAA-E053-731AD00AFE84","latestVersionIndicator":"Yes","beginDate":"2023-03-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-28","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7F6B052-E84C-4AAA-E053-731AD00AFE84","beginDate":"2023-03-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-28","modifiedBy":"SOKKERL","dateModified":"2023-03-28","deletedIndicator":"No"},{"value":"Not Reported","valueDescription":null,"ValueMeaning":{"publicId":"5612322","version":"1","preferredName":"Not Reported","longName":"5612322v1.00","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45340835-3B00-7C78-E053-F662850A44F9","latestVersionIndicator":"Yes","beginDate":"2017-01-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-01-03","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"10/10/23 changed Long Name from \"Not Stated\" to match NCIt Preferred name and current caDSR concept Long Name of \"Not Reported\" per Brenda.Janice . LS","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F7F6B052-E84D-4AAA-E053-731AD00AFE84","beginDate":"2023-03-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-28","modifiedBy":"SOKKERL","dateModified":"2023-03-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3284667","version":"1","preferredName":"Outcome Therapeutic Procedure Type","preferredDefinition":"The result of an action.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C20200:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9F740B-1B6C-4D44-E040-BB89AD432571","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"ONEDATA","dateModified":"2011-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C32E78-18C4-57DE-E050-BB89AD437A36","latestVersionIndicator":"Yes","beginDate":"2010-10-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":"Versioned to extend max length. mc 11/13/14","administrativeNotes":"2023.9.5 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787515","version":"1","longName":"PAAD","context":"NCIP"},{"publicId":"3787505","version":"1","longName":"HNSC","context":"NCIP"},{"publicId":"3787508","version":"1","longName":"KIRP","context":"NCIP"},{"publicId":"3787513","version":"1","longName":"LUSC","context":"NCIP"},{"publicId":"3787514","version":"1","longName":"OV","context":"NCIP"},{"publicId":"3787516","version":"1","longName":"PRAD","context":"NCIP"},{"publicId":"3787502","version":"1","longName":"CESC","context":"NCIP"},{"publicId":"3787503","version":"1","longName":"COAD","context":"NCIP"},{"publicId":"3787504","version":"1","longName":"GBM","context":"NCIP"},{"publicId":"3787506","version":"1","longName":"KICH","context":"NCIP"},{"publicId":"3787507","version":"1","longName":"KIRC","context":"NCIP"},{"publicId":"3787499","version":"1","longName":"BLCA","context":"NCIP"},{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"},{"publicId":"3787510","version":"1","longName":"LGG","context":"NCIP"},{"publicId":"3787509","version":"1","longName":"LAML","context":"NCIP"},{"publicId":"3787511","version":"1","longName":"LIHC","context":"NCIP"},{"publicId":"3787519","version":"1","longName":"SKCM","context":"NCIP"},{"publicId":"3787512","version":"1","longName":"LUAD","context":"NCIP"},{"publicId":"3787517","version":"1","longName":"READ","context":"NCIP"},{"publicId":"3787518","version":"1","longName":"SARC","context":"NCIP"},{"publicId":"3787520","version":"1","longName":"STAD","context":"NCIP"},{"publicId":"3787522","version":"1","longName":"UCEC","context":"NCIP"},{"publicId":"3787521","version":"1","longName":"THCA","context":"NCIP"}]},{"publicId":"5655939","version":"1","longName":"BLGSP (Burkitt Lymphoma Genome Sequencing Project)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000268","version":"1","longName":"Initial Treatment and Followup Form","context":"OCG"}]}],"AlternateNames":[{"name":"followup_treatment_success","type":"TCGA_XML_Name","context":"NCIP"},{"name":"OCG","type":"USED_BY","context":"OCG"},{"name":"follow-up_assessment_outcome_success","type":"HCMI Name","context":"OCG"}],"ReferenceDocuments":[{"name":"Measure of success of outcome","type":"Preferred Question Text","description":"Measure of success of outcome at the completion of this follow-up submission","url":null,"context":"NCIP"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"Treatment response at the completion of this follow-up submission","url":null,"context":"OCG"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C5819B-32A9-A68F-E050-BB89AD430FBA","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-11-13","modifiedBy":"TSESU","dateModified":"2018-07-10","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) by request of G. Diaz 5/2010 v2.0 replaces retired VD with current version. mc 9/23/11 Version 1 is retired - released v2 as part of maintenance. mc 10/20/11 Versioned to extend max length of VD. mc 11/13/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}